UNSPSC 51263166: Metipranolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H27NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FBW237ALKD, chemically known as 4-(2-hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate but more generally known as metipranolol hydrochloride, which bears US NIH Compound Identifier 31477. European Medicines Agency schedules Metipranolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03267MIG.

UNSPSC 51263166 Metipranolol hydrochloride is a Commodity code for a specific ophthalmic beta-blocker pharmaceutical; however, the recent solicitation activity tagged under this code does not align with the product's nominal scope. Seminole County, Florida posted an IFB (Invitation for Bid) in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually — opioid-reversal medication and harm-reduction equipment unrelated to metipranolol or ophthalmic pharmaceuticals. The mismatch suggests either a tagging error in the source data or that the jurisdiction applied the code outside its intended use. The work being solicited under this code tag is emergency response and public health commodity procurement, not pharmaceutical supply under the metipranolol classification.

Seminole County, a Florida county government entity, is the sole recent issuing body on record under this code. The procurement requires quarterly deliveries to a single location (Seminole County Community Health Building in Sanford, Florida), with an initial two-year term and one-year renewal option. Bidders must submit electronically, include all shipping and delivery costs in their proposal, and meet standard compliance requirements including drug-free workplace certification, E-Verify compliance, and specified insurance coverage. The contract is potentially FEMA-funded, introducing additional federal regulatory compliance. The response deadline was July 26, 2023 — a date now substantially in the past as of the current date. This code shows minimal recent activity consistent with its intended pharmaceutical scope, and any pursuit should verify the actual commodity classification before investing in business development.